Top 10 Companies in the Global High Purity Medical Grade Isosorbide Market (2026): Market Leaders Shaping Pharmaceutical Innovation

Market Insight

The Global High Purity Medical Grade Isosorbide market was valued at USD 239 million in 2023 and is projected to reach USD 373.96 million by 2032, exhibiting a CAGR of 5.10% during the forecast period.

Global High Purity Medical Grade Isosorbide Market – View in Detailed Research Report

Product Definition

Pharmaceutical Grade Isosorbide is a high‑purity chemical used in the pharmaceutical field. Isosorbide is a diol extracted from plant‑derived materials (such as corn starch) and belongs to cyclic sugar alcohols. It has good biocompatibility and biodegradability, so it is widely used in the pharmaceutical field.

Top 10 Companies in the Global High Purity Medical Grade Isosorbide Market

1️⃣ Roquette

Headquarters: Villerupt, France
Key Offering: High‑purity isosorbide for pharmaceutical and specialty chemical applications

Roquette’s portfolio of high‑purity isosorbide is leveraged in cardiovascular drug formulations and sustained‑release delivery systems. The company’s strong research pipeline positions it to capture emerging opportunities in advanced drug delivery.

Sustainability & Growth Initiatives:

• Expansion of biobased production capacity in Europe
• Investment in downstream technology for drug delivery systems
• Partnerships with leading pharma firms to co‑develop novel formulations

2️⃣ SK Holdings

Headquarters: Seoul, South Korea
Key Offering: Industrial isosorbide and specialty chemicals for pharma and polymer sectors

SK Holdings has positioned itself as a key supplier of high‑purity isosorbide to the Korean pharmaceutical market, supporting both domestic and export demand.

Sustainability & Growth Initiatives:

• Scale of renewable chemical production in Asia
• Collaboration with research institutions for polymer development
• Enhanced quality control to meet global pharma standards

3️⃣ Ecogreen Oleochemicals

Headquarters: Rotterdam, Netherlands
Key Offering: Renewable isosorbide and specialty chemicals

Ecogreen Oleochemicals focuses on renewable isosorbide derived from sustainable feedstocks, offering a green alternative for pharmaceutical manufacturers.

Sustainability & Growth Initiatives:

• Investment in green chemistry technologies
• Strategic alliances with European pharma companies
• Continuous improvement of biobased yield

4️⃣ ADM

Headquarters: Chicago, USA
Key Offering: High‑purity isosorbide from agricultural derivatives

ADM’s expertise in converting corn starch into high‑purity isosorbide supports the demand for biobased ingredients in drug delivery.

Sustainability & Growth Initiatives:

• Expansion of corn‑based production facilities in the Midwest
• Collaboration with pharma to develop next‑generation formulations
• Focus on reducing carbon footprint across the supply chain

5️⃣ Novaphene

Headquarters: New York, USA
Key Offering: Specialty isosorbide for polymer feedstock and drug delivery

Novaphene’s high‑purity isosorbide is utilized in both polymer synthesis and as a building block for controlled‑release pharmaceutical formulations.

Sustainability & Growth Initiatives:

• Investment in advanced polymer chemistry
• Partnerships with drug developers for sustained‑release technologies
• Commitment to sustainable manufacturing practices

6️⃣ BASF

Headquarters: Ludwigshafen, Germany
Key Offering: High‑purity isosorbide for pharma and polymer applications

BASF’s portfolio includes isosorbide derivatives that serve as excipients in cardiovascular drugs and as monomers for biodegradable polymers.

Sustainability & Growth Initiatives:

• Expansion of biobased production lines in Europe
• Research into biodegradable polymer blends
• Alignment with European sustainability regulations

7️⃣ Bayer

Headquarters: Leverkusen, Germany
Key Offering: Isosorbide derivatives for drug delivery and formulation

Bayer’s expertise in drug delivery systems positions it to incorporate isosorbide into advanced cardiovascular and sustained‑release products.

Sustainability & Growth Initiatives:

• Development of novel excipient technologies
• Collaboration with global pharma partners
• Focus on reducing waste in formulation processes

8️⃣ Dow

Headquarters: Midland, USA
Key Offering: High‑purity isosorbide for specialty chemicals and polymers

Dow’s high‑purity isosorbide supports the creation of polymeric materials with improved mechanical properties and biocompatibility.

Sustainability & Growth Initiatives:

• Investments in renewable feedstock utilization
• Partnerships with polymer manufacturers for green materials
• Efforts to lower energy consumption in production

9️⃣ DuPont

Headquarters: Wilmington, USA
Key Offering: Isosorbide for polymer and pharmaceutical applications

DuPont’s isosorbide portfolio is tailored for high‑performance polymers and pharmaceutical excipients, enhancing drug stability and delivery.

Sustainability & Growth Initiatives:

• Development of high‑yield production processes
• Collaboration with pharma to optimize formulation performance
• Commitment to carbon neutrality in manufacturing

🔟 LyondellBasell

Headquarters: Rotterdam, Netherlands
Key Offering: High‑purity isosorbide for polymer feedstock and specialty chemicals

LyondellBasell’s isosorbide is integral to producing biodegradable polymers and advanced drug delivery matrices.

Sustainability & Growth Initiatives:

• Expansion of biobased production capacity in Europe
• Research into polymer recycling technologies
• Partnerships with pharma for green formulation solutions

Download FREE Sample Report

Download FREE Sample Report: Global High Purity Medical Grade Isosorbide Market – View in Detailed Research Report

Get Full Report

Get Full Report: Global High Purity Medical Grade Isosorbide Market – View in Detailed Research Report

Outlook

The trajectory of the High Purity Medical Grade Isosorbide market is shaped by the growing demand for cardiovascular drugs and sustained‑release delivery systems. Europe maintains a leading position with 40% of the global share, while North America’s market is expanding at a 4.37% CAGR. The shift toward biobased production and stringent regulatory requirements for pharmaceutical excipients will drive further consolidation among key players.

Future Trends

• Increased adoption of isosorbide in sustained‑release cardiovascular formulations
• Growth of biobased manufacturing capacities across Asia‑Pacific
• Emergence of isosorbide‑based biodegradable polymers for drug delivery
• Enhanced collaboration between chemical suppliers and pharma developers
• Focus on cost‑effective production technologies to maintain margin